TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03254108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-61815 injection 2mg
Description: Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 2 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-61815 injection 4mg
Description: Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 4 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-61815 injection 8mg
Description: Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 8 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-61815 injection 16mg
Description: Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolvaptan tablet 15mg
Description: Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo.
Study: NCT03758300

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Radiofrequency
Description: See previous page

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiofrequency
Description: See previous page
Study: NCT00894959

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Heparin sodium Blausiegel 1
Description: Heparin sodium Blausiegel 1 5.000 UI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Heparin sodium APP
Description: Heparin sodium APP 5.000 USP
Study: NCT03698344

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biodiesel exhaust exposure
Description: Evaluation of sympathetic nervous system activity as assessed by microneurography recording during an acute exposure to dilute biodiesel exhaust via mask.
Study: NCT00608946

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: copper
Description: intake of copper orotate 8 mg per day per os, once daily for one year, vs. placebo under observation of the cognitive status

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT01325337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost Formulation A
Description: Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost Formulation B
Description: Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost Formulation C
Description: Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bimatoprost vehicle solution
Description: Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: minoxidil 5% solution
Description: Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months.
Study: NCT03286673

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: calcium phosphate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tricalcium Phosphate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium carbonate
Study: NCT02799251

Intervention type: OTHER
Intervention: Collection of plasma cell rate
Description: Lymphocytes counts are obtained from patients undergoing pulmonary or digestive cancer surgery. The rates are assessed before surgery (day 0) and at days 1, 3, 5 and 8 after surgery. Anesthetic and surgical procedures are collected as well as risk factors for postoperative infections recognized in the literature. Clinical and biological signs of infection are collected.
Study: NCT03286673

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT04551014

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of EverLift
Description: Use of EverLift for submucosal injection prior to polypectomy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Without use of EverLift
Description: Without use of EverLift for submucosal injection prior to polypectomy
Study: NCT02221492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plerixafor GZ316455
Description: Pharmaceutical form:vial Route of administration: subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim
Description: Pharmaceutical form:vial Route of administration: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Pharmaceutical form:vial Route of administration: subcutaneous injection
Study: NCT02654002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilofexor
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilofexor
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilofexor
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilofexor
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilofexor
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilofexor
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilofexor
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilofexor
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilofexor
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilofexor
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets administered orally
Study: NCT03457441

Intervention type: OTHER
Group type: OTHER
Intervention: Standards vision tests
Description: Subjects vision : near visual acuity, contrast sensitivity and scotoma and metamorphopsia detection will be assessed by gold-standard tests and with the OdySight medical application

Intervention type: OTHER
Group type: OTHER
Intervention: Standards vision tests
Description: Subjects vision : near visual acuity, contrast sensitivity and scotoma and metamorphopsia detection will be assessed by gold-standard tests and with the OdySight medical application

Intervention type: OTHER
Group type: OTHER
Intervention: Standards vision tests
Description: Subjects vision : near visual acuity, contrast sensitivity and scotoma and metamorphopsia detection will be assessed by gold-standard tests and with the OdySight medical application

Intervention type: DEVICE
Group type: OTHER
Intervention: OdySight medical application assessment
Description: Subjects vision : near visual acuity, contrast sensitivity and scotoma and metamorphopsia detection will be assessed by gold-standard tests and with the OdySight medical application

Intervention type: DEVICE
Group type: OTHER
Intervention: OdySight medical application assessment
Description: Subjects vision : near visual acuity, contrast sensitivity and scotoma and metamorphopsia detection will be assessed by gold-standard tests and with the OdySight medical application

Intervention type: DEVICE
Group type: OTHER
Intervention: OdySight medical application assessment
Description: Subjects vision : near visual acuity, contrast sensitivity and scotoma and metamorphopsia detection will be assessed by gold-standard tests and with the OdySight medical application
Study: NCT02230969

Intervention type: DRUG
Intervention: peginterferon beta-1a
Description: Administered as specified in the treatment arm
Study: NCT03319745

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT02654002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets administered orally
Study: NCT00891202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eliglustat tartrate
Description: PAP: Eliglustat tartrate (ET) capsule 50 mg orally on Day 1 followed by ET 50 mg capsule twice daily (BID) from Day 2 to Week 4, then either ET 50 mg capsule BID (participants with Genz-99067 \[active moiety of ET in plasma\] trough plasma concentration \>=5 ng/mL) or ET 100 mg capsule BID (participants with Genz-99067 trough plasma concentration \<5 ng/mL), up to Week 39. PK assessment at Week 2 used for dose adjustment after Week 4. LTTP: Participants of the eliglustat arm in PAP who completed PAP were included in LTTP and received ET capsule 50 mg BID orally from Day 1 (post Week 39) until Week 43 followed by ET 50 mg or 100 mg capsule BID up to Week 47, then ET 50 mg or 100 mg or 150 mg capsule BID up to Week 312. Dose adjustments at Week 43 and Week 47 were based on Genz-99067 trough plasma concentrations (if trough plasma concentration \<5 ng/mL: next higher dose administered; if \>=5 ng/mL: same dose continued) at Week 41 \& Week 45, respectively.
Study: NCT03254459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine Sublingual Spray
Description: 0.5 mg Sublingual Spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: 4 mg Intravenous Injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone Hydrochloride
Description: 10 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zofran
Description: 4 mg oral disintegrating tablet (ODT) or IV injection given at the investigator's discretion for nausea

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zofran
Description: 4 mg oral disintegrating tablet (ODT) or IV injection given at the investigator's discretion for nausea
Study: NCT00979667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: 75 mg twice daily for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanamivir
Description: 10 mg twice daily for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Oseltamivir
Description: twice daily for 5 days
Study: NCT01237483

Intervention type: DRUG
Group type: OTHER
Intervention: Erbitux
Description: To begin 7 days before radiotherapy, loading dose 400 mg / m² in the first week then 250 mg / m² weekly for the duration of radiotherapy (for a total of 7 doses including the loading dose)
Study: NCT00265356

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET diagnostic imaging
Description: PET diagnostic imaging
Study: NCT01737229

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Application of Biodentine™ (RD94), dentin substitute

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Application of Biodentine™ (RD94), dentin substitute

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Application of Biodentine™ (RD94), dentin substitute

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Application of Biodentine™ (RD94), dentin substitute

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Application of Biodentine™ (RD94), dentin substitute

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Application of Biodentine™ (RD94), dentin substitute
Study: NCT04518189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine patch
Description: lidocaine patch applied 3 hours before the procedure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sham patch
Description: Sham patch applied 3 hours before the procedure
Study: NCT00307320

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation Training
Description: Relaxation techniques training
Study: NCT02923024

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Ping
Description: The patient ping will be a fax sent from Oscar Health to physician that will include information on the physician's patient's trigger event and contact information for the physician to reach out to the member.
Study: NCT00891202

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PAP: Matching placebo capsule once daily on Day 1 followed by matching placebo capsule BID from Day 2 through Week 39. LTTP: Participants of the placebo arm in PAP who completed PAP were included in LTTP and received eliglustat tartrate from Day 1 (post Week 39) up to Week 312. Day 1 (post Week 39) was considered as baseline for LTTP. On Day 1, participants received eliglustat tartrate capsule 50 mg BID orally until Week 43 followed by eliglustat tartrate 50 mg or 100 mg capsule BID up to Week 47, then eliglustat tartrate 50 mg or 100 mg or 150 mg capsule BID up to Week 312. Dose adjustments at Week 43 and Week 47 were based on Genz-99067 trough plasma concentrations (if trough plasma concentration \<5 ng/mL: next higher dose administered; if \>=5 ng/mL: same dose continued) at Week 41 \& Week 45, respectively.
Study: NCT03951636

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Mechanical debridement with curettes
Description: mechanical debridement: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Description: mechanical debridement: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments. Furthermore, an Er:YAG laser will be used for the implant surface decontamination.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Air Powder
Description: mechanical debridement: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments. Furthermore, an Air-Powder treatment will be provided on the implant/abutment surface.
Study: NCT01495143

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Posterolateral lumbar fusion surgery
Description: Two MD catheters with 1% lidocaine 1-2 ml are placed in the paraspinal muscle.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterolateral lumbar fusion surgery
Description: Two MD catheters with 1% lidocaine 1-2 ml are placed in the paraspinal muscle.
Study: NCT02249637

Intervention type: PROCEDURE
Intervention: Novel technique Circumcision Incision Orchidopexy
Description: The novel technique starts with retraction of the prepucial skin off the glans penis and double incision circumcision done with mucosal sparing, then degloving of the penis on the side of the undescended testis. Dissection via Dartos' layer into the inguinal area until the palpable testicle was identified and extracted with mobilization of the spermatic cord. Hernia sac was then separated and suture ligated as high as the area of internal ring opening. Spematic cord lengthening was done until adequate length achieved for fixation into the inferior aspect of the scrotum. Then development of the Dartos' pouch via the circumcision site was done. A double or single suture testicular fixation using Vicryl 3-0 simple interrupted sutures on the everted Dartos' pouch inner surface was done. Subsequent placement of the testicle into the Dartos' pouch was done as the inner surface was inverted. The last step was the completion of the circumcision closure using Chromic 4-0 interrupted sutures.
Study: NCT03648866

Intervention type: OTHER
Intervention: interview
Description: Initial interview and potential follow-up interviews and focus group with Florida Hospital employees.~Interview participants in compassion rounds
Study: NCT00684177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retapamulin Ointment, 1%
Description: Provided as approximately 10 grams of an off-white smooth ointment in collapsible aluminum tubes with reverse taper puncture tip caps.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ointment
Description: Provided as approximately 10 grams of an off-white smooth ointment in collapsible aluminum tubes with reverse taper puncture tip caps.
Study: NCT01446809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo external beam radiation therapy

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: External Beam Radiation Therapy
Description: Undergo external beam radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ifosfamide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib Hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study: NCT04175470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/kg intravenously every three weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/kg intravenously every three weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tocotrienol
Description: Capsules, 300 mg orally three times daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tocotrienol
Description: Capsules, 300 mg orally three times daily
Study: NCT05114772

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Measuring Serum bio-markers
Description: ELISA Estimation of Serum visfatin and tumor necrosis factor-alpha

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Measuring Serum bio-markers
Description: ELISA Estimation of Serum visfatin and tumor necrosis factor-alpha
Study: NCT03396770

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard clinical routine
Description: Patient management is carried out according to the usual service protocol

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nephrocheck test
Description: Nephrocheck® test is realized 4 hours after the end of the cardiopulmonary bypass~* If the test is positive, hemodynamic evaluation is carried out and adapted therapy to result of this evaluation is initiated.~* If the test is negative, patient management is carried out according to the usual protocol.~* A second test is realized 6 hours after the first test whatever the result of it.
Study: NCT02363478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buspirone
Description: buspirone 10 mg X2 for 4 weeks
Study: NCT03402776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4th dose of hexavalent vaccine 1 month after the 3rd dose
Description: 4th dose of hexavalent vaccine 1 month after the 3rd dose
Study: NCT02424279

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Splanchnicectomy
Study: NCT04802473

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mucogingival surgery
Description: In brief description, Tunnel+acellular dermal matrix treatment will be performed by starting initial sulcular incisions, tunneling knives will be used to elevate the buccal gingiva by means of a full-thickness flap elevation. Flap preparation will be extended beyond the MGJ. The exposed root surfaces will be treated with pre-conditioning EDTA (Straumann PrefGel®) for 2 minutes. ADM (OrACELL, LifeNet Helth, Virginia Beach, VA, USA) of 1.25-1.75mm in thickness will be cut to the exact size of the defect, and will be inserted into the tunnel, and subsequently covered advancing the flap by means of sling sutures to stabilize the flap in a coronal position (6-0 Polypropylene, Prolene, Ethicon, Johnson and Johnson, New Brunswick, NJ, USA). Sutures will be removed after 14 days. Two weeks after surgery, patients will resume mechanical tooth cleaning with a soft toothbrush. Patients will be recalled at 1, 3 and 6 months for professional oral hygiene procedures.
Study: NCT01402245

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal polysaccharide vaccine
Description: Pneumococcal polysaccharide vaccine 0.5 ml i.m.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: pneumococcal conjugate vaccine
Description: pneumococcal conjugate vaccine 0.5 ml i.m.
Study: NCT01292967

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Low flavanol chocolate
Description: 48 mg of total flavanols from cocoa

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High-flavanol with sugar
Description: high-flavanol containing 251 mg cocoa flavanols

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High flavanol Maltitol
Description: high-flavanol containing 266 mg cocoa flavanols
Study: NCT03038308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole
Description: 0.25mg/day - 6.0mg/day oral non-ergoline dopamine agonist ropinirole
Study: NCT04314050

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: tramadol and paracetamol will perform

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: dexmedetomidine and paracetamol will perform

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: paracetamol will perform